Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus LEVORA 0 15 30 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus LEVORA 0 15 30 21.
ENSKYCE vs LEVORA 0.15/30-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; levonorgestrel inhibits ovulation and thickens cervical mucus, impairing sperm penetration. Also induces endometrial atrophy.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet orally once daily for 21 days, followed by 7 tablet-free days.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
20-30 hours for ethinyl estradiol; 2-4 hours for levonorgestrel. Steady-state reached in 5-7 days
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Urine (50-60% as metabolites), feces (30-40% as glucuronides); <10% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive